LNCD(SH:600739) Ge Long Hui A P P·2026-01-26 09:58Core Viewpoint - Liaoning Chengda (600739.SH) plans to establish a biopharmaceutical investment fund to enhance its competitiveness and seize market opportunities, with a total fund size not exceeding 100 million yuan, and an initial size of 50.2 million yuan [1][2] Group 1: Fund Structure and Contributions - The fund will be managed by Chengda Coastal as the general partner, contributing 1 million yuan, which accounts for 0.1992% of the initial fund size [1] - Shenzhen Chengda Biotech will also act as a general partner, contributing 1 million yuan, representing 0.1992% of the initial fund size [1] - Liaoning Chengda will contribute 10 million yuan as a limited partner, making up 19.9203% of the initial fund size [1] - Chengda Biotech will contribute 40 million yuan as a limited partner, accounting for 79.6813% of the initial fund size [1] Group 2: Fund Investment Focus and Future Plans - The fund will focus on the life and health industry during its investment period, with plans to raise the total contribution to 100 million yuan within three years [2] - Shenzhen Chengda Biotech and Chengda Medical plan to increase their investment in Gene Qiming, with Shenzhen Chengda Biotech contributing 40 million yuan and Chengda Medical contributing 10 million yuan [2] - After the fund is legally established, it will acquire all shares of Gene Qiming held by Shenzhen Chengda Biotech and Chengda Medical, allowing the company to indirectly enjoy related rights through the fund [2]